Moderna stock more than doubled at its premarket peak Wednesday after the company’s personalized mRNA cancer treatment, developed with Merck, succeeded in a pivotal Phase 3 melanoma trial. MRNA rose by approximately 105% from Tuesday’s $62.96 closing price, reaching an estimated peak near $129.07.
Visit Website